end
novel
coronaviru
name
sever
acut
respiratori
syndrom
coronaviru
result
acut
respiratori
ill
epidem
wuhan
china
world
health
organ
term
ill
coronaviru
diseas
covid
time
guidelin
panel
assembl
becom
pandem
affect
individu
countri
result
death
worldwid
unit
state
center
diseas
control
prevent
cdc
issu
preliminari
guidanc
infect
control
screen
diagnosi
gener
popul
limit
guidanc
acut
manag
critic
ill
patient
sever
ill
due
guidelin
provid
recommend
support
hospit
clinician
manag
critic
ill
adult
intens
care
unit
icu
target
user
guidelin
frontlin
clinician
alli
health
profession
policymak
involv
care
patient
icu
guidelin
appli
high
lowmiddl
incom
set
surviv
sepsi
campaign
ssc
subcommitte
select
panel
member
way
obtain
balanc
topic
expertis
geograph
locat
far
possibl
gender
ssc
panel
assembl
work
within
tight
timelin
order
issu
recommend
time
manner
panel
includ
expert
guidelin
develop
infect
control
infecti
diseas
microbiolog
critic
care
emerg
medicin
nurs
public
health
panel
divid
four
group
infect
control
test
hemodynam
support
ventilatori
support
therapi
guidelin
intens
care
develop
evalu
guid
group
provid
methodolog
support
throughout
guidelin
develop
process
panel
member
complet
conflict
interest
coi
form
prior
join
guidelin
panel
use
gradepro
guidelin
develop
tool
gdt
onlin
softwar
http
gdtguidelinedevelopmentorg
administ
coi
disclosur
form
particip
panel
member
direct
financi
industryrel
coi
permit
consid
disqualifi
develop
guidelin
includ
industri
input
fund
financi
nonfinanci
contribut
member
guidelin
panel
receiv
honoraria
remuner
role
guidelin
develop
process
guidelin
develop
process
summar
figur
action
guidelin
question
structur
popul
intervent
control
outcom
pico
format
explicit
definit
wherea
descript
question
content
method
expert
group
particip
develop
guidelin
question
pico
format
provid
basi
defin
inclus
exclus
criteria
literatur
search
perform
identif
relev
studi
facilit
rapid
develop
recommend
perform
novel
systemat
priorit
outcom
use
outcom
priorit
inform
ongo
ssc
guidelin
work
expert
input
accordingli
focus
hospit
mortal
seriou
advers
event
outcom
question
includ
outcom
deem
critic
decis
make
question
help
profession
medic
librarian
electron
search
major
databas
ie
cochran
central
medlin
identifi
relev
systemat
review
random
control
trial
rct
observ
studi
case
seri
electron
search
perform
look
studi
publish
english
incept
march
inform
recommend
hemodynam
ventilatori
support
use
recent
publish
systemat
review
ask
expert
identifi
new
relev
studi
select
pico
question
pair
review
screen
titl
abstract
retriev
bibliograph
databas
pico
question
potenti
elig
studi
assess
elig
accord
prespecifi
criteria
content
expert
ask
indic
addit
studi
identifi
search
subsequ
pair
review
independ
abstract
relev
data
correspond
pico
question
item
relev
risk
bia
obtain
intentiontotreat
data
whenev
avail
otherwis
use
complet
case
data
ie
ignor
miss
data
use
grade
recommend
assess
develop
evalu
grade
approach
assess
qualiti
evid
ie
confid
estim
effect
support
recommend
qualiti
evid
rate
high
moder
low
low
use
gdt
onlin
softwar
http
gdtguidelinedevelopmentorg
gener
evid
profil
evid
summari
given
recent
emerg
anticip
would
scarciti
direct
evid
therefor
use
predefin
algorithm
decid
whether
indirect
evid
could
inform
specif
question
fig
supplement
digit
content
http
ssc
panel
decid
popul
extrapol
evid
base
context
recommend
likelihood
presenc
effect
modifi
fig
supplement
digit
content
http
linkslwwcom
accordingli
use
sourc
indirect
evid
data
middl
east
respiratori
syndrom
coronaviru
merscov
sever
acut
respiratori
syndrom
sar
coronavirus
way
consid
indirect
evid
publish
data
support
care
icu
studi
influenza
respiratori
viral
infect
acut
respiratori
distress
syndrom
ard
sepsi
healthcar
worker
perform
aerosolgener
procedur
patient
icu
recommend
use
fit
respir
mask
respir
equival
oppos
surgic
medic
mask
addit
person
protect
equip
ie
glove
gown
eye
protect
face
shield
safeti
goggl
best
practic
statement
respir
mask
design
block
aerosol
particl
type
conform
unit
state
feder
drug
agenc
standard
conform
european
standardseuropean
committe
standard
standard
staff
fit
test
differ
type
surgic
mask
also
known
medic
mask
design
block
larg
particl
droplet
spray
less
effect
block
small
particl
aerosol
recommend
base
consensu
recommend
cdc
public
health
organ
along
epidemiolog
data
demonstr
aerosolgener
procedur
increas
risk
healthcar
worker
sar
epidem
power
air
purifi
respir
papr
use
healthcar
worker
fail
mask
fit
test
limit
suppli
recommend
perform
aerosolgener
procedur
icu
patient
neg
pressur
room
best
practic
statement
neg
pressur
room
engin
control
intend
prevent
spread
contagi
airborn
pathogen
healthcar
worker
perform
aerosolgener
procedur
patient
icu
recommend
use
fit
respir
mask
respir
equival
oppos
surgicalmed
mask
addit
person
protect
equip
ie
glove
gown
eye
protect
face
shield
safeti
goggl
best
practic
statement
recommend
perform
aerosolgener
procedur
icu
patient
neg
pressur
room
best
practic
statement
healthcar
worker
provid
usual
care
nonventil
patient
suggest
use
surgicalmed
mask
oppos
respir
mask
addit
person
protect
equip
ie
glove
gown
eye
protect
face
shield
safeti
goggl
healthcar
worker
perform
nonaerosolgener
procedur
mechan
ventil
close
circuit
patient
suggest
use
surgicalmed
mask
oppos
respir
mask
addit
person
protect
equip
ie
glove
gown
eye
protect
face
shield
safeti
goggl
adult
shock
suggest
use
dynam
paramet
skin
temperatur
capillari
refil
time
andor
serum
lactat
measur
static
paramet
order
assess
fluid
respons
acut
resuscit
adult
shock
suggest
use
conserv
liber
fluid
strategi
acut
resuscit
adult
shock
recommend
use
crystalloid
colloid
acut
resuscit
adult
shock
suggest
use
buffer
balanc
crystalloid
unbalanc
crystalloid
acut
resuscit
adult
shock
recommend
use
hydroxyethyl
starch
acut
resuscit
adult
shock
suggest
use
gelatin
weak
acut
resuscit
adult
shock
suggest
use
dextran
acut
resuscit
adult
shock
suggest
routin
use
albumin
initi
resuscit
adult
acut
hypoxem
respiratori
failur
oxygen
recommend
spo
maintain
higher
adult
acut
hypoxem
respiratori
failur
despit
convent
oxygen
therapi
suggest
use
hfnc
convent
oxygen
therapi
adult
acut
hypoxem
respiratori
failur
suggest
use
hfnc
nippv
adult
acut
hypoxem
respiratori
failur
hfnc
avail
urgent
indic
endotrach
intub
suggest
trial
nippv
close
monitor
shortinterv
assess
worsen
respiratori
failur
abl
make
recommend
regard
use
helmet
nippv
compar
mask
nippv
option
certain
safeti
efficaci
adult
receiv
nippv
hfnc
recommend
close
monitor
worsen
respiratori
statu
earli
intub
control
set
worsen
occur
best
practic
statement
mechan
ventil
adult
ard
recommend
use
low
tidal
volum
vt
ventil
vt
mlkg
predict
bodi
weight
higher
tidal
volum
vt
mlkg
perform
within
room
lower
risk
crosscontamin
among
room
infect
staff
patient
outsid
room
neg
pressur
creat
maintain
ventil
system
allow
extra
air
enter
isol
room
differenti
pressur
exhaust
directli
outsid
filter
higheffici
particul
air
hepa
filter
directli
recircul
moreov
presenc
unnecessari
staff
room
avoid
mechan
ventil
adult
sever
ard
hypoxemia
despit
optim
ventil
rescu
strategi
suggest
trial
inhal
pulmonari
vasodil
rescu
therapi
rapid
improv
oxygen
observ
treatment
taper
mechan
ventil
adult
hypoxemia
despit
optim
ventil
suggest
use
recruit
maneuv
use
recruit
maneuv
recruit
maneuv
use
recommend
use
staircas
increment
peep
recruit
maneuv
mechan
ventil
adult
refractori
hypoxemia
despit
optim
ventil
use
rescu
therapi
prone
suggest
use
venoven
vv
ecmo
avail
refer
patient
ecmo
center
remark
due
resourceintens
natur
ecmo
need
experienc
center
healthcar
worker
infrastructur
ecmo
consid
care
select
patient
sever
ard
weak
therapi
mechan
ventil
adult
respiratori
failur
without
ard
suggest
routin
use
system
corticosteroid
mechan
ventil
adult
ard
suggest
use
system
corticosteroid
use
corticosteroid
remark
major
panel
support
weak
recommend
ie
suggest
use
steroid
sickest
patient
ard
howev
lowqual
evid
expert
panel
prefer
issu
recommend
higher
qualiti
direct
evid
avail
mechan
ventil
patient
respiratori
failur
suggest
use
empir
antimicrobialsantibacteri
agent
antimicrobi
remark
treat
team
initi
empir
antimicrobi
assess
deescal
daili
reevalu
durat
therapi
spectrum
coverag
base
microbiolog
result
patient
clinic
statu
critic
ill
adult
develop
fever
suggest
use
acetaminophenparacetamol
temperatur
control
treatment
critic
ill
adult
suggest
routin
use
standard
intraven
immunoglobulin
ivig
critic
ill
adult
suggest
routin
use
convalesc
plasma
weak
critic
ill
adult
suggest
routin
use
lopinavirritonavir
weak
insuffici
evid
issu
recommend
use
antivir
agent
critic
ill
adult
insuffici
evid
issu
recommend
use
recombin
rifn
alon
combin
antivir
critic
ill
adult
insuffici
evid
issu
recommend
use
chloroquin
hydroxychloroquin
critic
ill
adult
insuffici
evid
issu
recommend
use
tocilizumab
critic
ill
adult
recommend
neg
pressur
room
proven
effect
measur
help
avoid
crosscontamin
sar
epidem
accordingli
aerosolgener
procedur
guidanc
recommend
use
neg
pressur
room
minimum
air
chang
per
hour
least
lsecpati
facil
natur
ventil
bronchoscopi
among
procedur
highest
risk
aerosol
use
minim
noninvas
ventil
also
high
risk
aerosol
strategi
describ
contain
risk
viru
spread
also
accord
previou
report
sar
infect
feasibl
portabl
hepa
filter
use
room
wherev
possibl
hepa
filter
mechan
air
filter
use
isol
maximum
reduct
remov
submicron
particul
matter
air
requir
hepa
filter
demonstr
reduc
viru
transmiss
simul
set
healthcar
worker
provid
usual
care
nonventil
patient
suggest
use
surgicalmed
mask
oppos
respir
mask
addit
person
protect
equip
ie
glove
gown
eye
protect
face
shield
safeti
goggl
weak
recommend
lowqual
evid
healthcar
worker
perform
nonaerosolgener
procedur
mechan
ventil
close
circuit
patient
suggest
use
surgic
medic
mask
oppos
respir
mask
addit
person
protect
equip
ie
glove
gown
eye
protect
face
shield
safeti
goggl
weak
recommend
lowqual
evid
recommend
line
guidanc
current
evid
suggest
surgic
medic
mask
probabl
inferior
respir
provid
protect
laboratori
confirm
season
respiratori
viral
infect
eg
influenza
measl
updat
recent
systemat
review
metaanalysi
rct
identifi
one
new
rct
overal
four
rct
individu
random
healthcar
worker
respir
medic
mask
respir
group
make
recommend
panel
consid
lack
convinc
evid
respir
improv
clinic
outcom
cost
resourc
associ
mask
use
need
preserv
respir
suppli
aerosolgener
procedur
therefor
panel
issu
suggest
use
medic
mask
context
howev
appear
easili
transmiss
lethal
season
influenza
specif
earli
estim
reproduct
number
r
averag
number
peopl
infect
person
subsequ
infect
function
biolog
properti
pathogen
combin
social
environment
factor
comparison
estim
averag
r
influenza
pandem
result
estim
million
death
global
estim
averag
r
season
influenza
therefor
minimum
surgicalmed
mask
recommend
healthcar
worker
care
nonventil
patient
healthcar
worker
perform
nonaerosolgener
procedur
mechan
ventil
close
circuit
patient
scarciti
issu
use
fit
respir
use
fit
respir
mask
reason
option
healthcar
worker
perform
endotrach
intub
patient
suggest
use
videoguid
laryngoscopi
direct
laryngoscopi
avail
weak
recommend
lowqual
evid
direct
evid
compar
use
videolaryngoscopi
direct
laryngoscopi
intub
patient
appear
predominantli
spread
larg
respiratori
droplet
intub
like
small
particl
less
aerosolgener
procedur
increas
risk
transmiss
healthcar
worker
intub
particularli
riski
given
close
contact
healthcar
worker
patient
airway
respiratori
secret
thu
techniqu
reduc
number
attempt
endotrach
intub
durat
procedur
minim
proxim
oper
patient
priorit
potenti
reduc
risk
complic
hypox
patient
patient
difficult
airway
firstattempt
success
rate
may
improv
videolaryngoscopi
thu
set
videolaryngoscopi
avail
staff
skill
use
suggest
use
prefer
direct
laryngoscopi
maxim
chanc
success
recogn
center
rapid
access
videolaryngoscopi
skill
user
recommend
condit
recommend
endotrach
intub
perform
healthcar
worker
experienc
airway
manag
order
minim
number
attempt
risk
transmiss
best
practic
statement
similar
reason
factor
maxim
chanc
first
pass
success
use
intub
patient
suspect
confirm
thu
recommend
healthcar
oper
experi
skill
airway
manag
first
attempt
intub
recent
declar
pandem
accordingli
everi
critic
ill
patient
arriv
evid
respiratori
infect
consid
potenti
infect
realtim
polymeras
chain
reaction
rtpcr
gold
standard
similar
viral
infect
includ
sar
notabl
pose
sever
diagnost
challeng
due
extend
incub
period
approxim
two
week
includ
prolong
interv
approxim
day
viral
shed
prior
onset
symptom
moreov
durat
asymptomat
shed
variabl
may
also
differ
base
anatom
level
upper
versu
lower
infect
respiratori
system
accordingli
perform
biomolecular
assay
may
vari
site
sampl
intub
mechan
ventil
adult
suspicion
diagnost
test
suggest
obtain
lower
respiratori
tract
sampl
prefer
upper
respiratori
tract
nasopharyng
oropharyng
sampl
weak
recommend
lowqual
evid
regard
lower
respiratori
sampl
suggest
obtain
endotrach
aspir
prefer
bronchial
wash
bronchoalveolar
lavag
sampl
weak
recommend
lowqual
evid
diagnosi
base
rtpcr
test
respiratori
sampl
nasopharyng
oropharyng
swab
lower
respiratori
tract
sampl
whenev
possibl
bronchoalveolar
lavag
limit
perform
indic
adequ
precaut
due
risk
aerosol
consequ
exposur
healthcar
profession
similarli
sputum
induct
avoid
due
increas
risk
aerosol
tracheal
aspir
specimen
appear
carri
lower
risk
aerosol
sometim
obtain
without
disconnect
patient
ventil
procedur
involv
laboratori
rtpcr
test
use
number
assay
current
use
well
describ
despit
gener
high
sensit
specif
rtpcrbase
assay
may
enough
reli
oropharyng
swab
specimen
alon
diagnosi
due
low
neg
predict
valu
recent
studi
oropharyng
swab
patient
test
posit
rtpcr
similar
data
report
use
rtpcr
sar
epidem
use
seroconvers
gold
standard
sar
diagnosi
rtpcr
assay
perform
nasopharyng
throat
specimen
posit
time
respect
howev
fals
posit
observ
indic
assay
specif
similarli
studi
account
ct
scan
find
among
suspect
case
neg
oropharyng
nasal
swab
consid
highli
like
case
consid
probabl
case
consequ
singl
neg
swab
upper
airway
rule
infect
repeat
sampl
multipl
site
includ
lower
airway
increas
diagnost
yield
similarli
given
coinfect
viral
pathogen
observ
posit
test
anoth
respiratori
viru
rule
delay
test
high
suspicion
given
high
specif
singl
posit
swab
confirm
diagnosi
enough
trigger
infect
control
precaut
appropri
treatment
patient
lower
respiratori
tract
specimen
consid
give
higher
diagnost
yield
upper
respiratori
specimen
patient
pneumonia
consist
observ
sar
therefor
obtain
whenev
possibl
report
preval
shock
adult
patient
highli
variabl
depend
patient
popul
studi
sever
ill
definit
shock
recent
report
summar
epidemiolog
characterist
chines
patient
diagnos
critic
case
defin
sever
hypoxemia
andor
presenc
organ
failur
includ
shock
anoth
chines
studi
patient
similar
sever
ill
develop
shock
hospit
patient
incid
like
higher
cardiac
injuri
elev
cardiac
injuri
biomark
percentil
upper
refer
limit
report
patient
wuhan
china
preval
cardiac
injuri
may
correl
preval
shock
lack
systemat
screen
cardiac
dysfunct
hemodynam
stabl
patient
mean
associ
taken
certain
tabl
prognosi
patient
shock
systemat
report
studi
patient
hospit
wuhan
china
shock
major
reason
death
may
least
part
due
fulmin
myocard
studi
risk
factor
associ
shock
patient
lack
major
avail
report
unadjust
estim
despit
methodolog
limit
studi
suggest
older
age
comorbid
especi
diabet
cardiovascular
diseas
includ
hypertens
lower
lymphocyt
count
higher
ddimer
level
possibl
cardiac
injuri
risk
factor
consid
adult
shock
suggest
use
dynam
paramet
skin
temperatur
capillari
refil
time
andor
serum
lactat
measur
static
paramet
order
assess
fluid
respons
weak
recommend
lowqual
evid
direct
evid
address
optim
resuscit
strategi
patient
shock
therefor
panel
base
recommend
indirect
evid
drawn
critic
ill
patient
gener
systemat
review
metaanalysi
rct
n
examin
effect
dynam
assess
fluid
therapi
import
patient
outcom
adult
icu
patient
requir
fluid
resuscit
use
dynam
assess
guid
fluid
therapi
found
reduc
mortal
rr
ci
icu
length
stay
md
day
ci
durat
mechan
ventil
hour
ci
note
one
trial
focus
patient
septic
shock
dynam
paramet
use
trial
includ
stroke
volum
variat
svv
puls
pressur
variat
ppv
stroke
volum
chang
passiv
leg
rais
fluid
challeng
among
examin
dynam
paramet
passiv
leg
rais
follow
ppv
svv
appear
predict
fluid
respons
highest
accuraci
static
paramet
includ
compon
earli
goaldirect
therapi
eg
central
venou
pressur
cvp
mean
arteri
pressur
map
use
serum
lactat
level
guid
resuscit
patient
shock
summar
systemat
review
metaanalysi
seven
rct
n
compar
central
venou
oxygen
satur
guid
therapi
earli
lactat
clearancedirect
therapi
associ
reduct
mortal
rr
ci
shorter
icu
length
stay
md
day
ci
shorter
durat
mechan
ventil
md
hour
ci
howev
high
lactat
level
alway
indic
hypovolemia
may
also
caus
mitochondri
dysfunct
liver
failur
betaagonist
mesenter
ischemia
epinephrin
andromedashock
trial
capillari
refil
test
crt
everi
min
associ
nonsignific
reduct
mortal
hr
ci
compar
serum
lactat
measur
everi
hour
crt
simpl
easi
test
use
almost
set
given
possibl
improv
mortal
length
stay
durat
mechan
ventil
may
produc
well
avail
suggest
use
dynam
paramet
skin
temperatur
capillari
refil
time
andor
lactat
measur
static
paramet
assess
fluid
respons
patient
shock
acut
resuscit
adult
shock
suggest
use
conserv
liber
fluid
strategi
weak
recommend
lowqual
evid
direct
evid
exist
patient
shock
therefor
panel
use
indirect
evid
critic
ill
patient
sepsi
ard
inform
recommend
recent
systemat
review
rct
n
patient
compar
restrict
versu
liber
fluid
volum
initi
resuscit
patient
sepsi
found
statist
signific
differ
mortal
rr
ci
seriou
advers
event
rr
ci
howev
assess
outcom
favor
conserv
fluid
therapi
lower
volum
importantli
quantiti
qualiti
evid
judg
low
suggest
research
need
correspondingli
metaanalysi
rct
n
patient
adult
children
ard
sepsi
manag
accord
conserv
fluid
strategi
postresuscit
phase
critic
ill
ventilatorfre
day
shorter
icu
stay
patient
manag
accord
liber
fluid
strategi
see
section
respiratori
support
detail
larg
rct
febril
african
children
feast
found
children
random
fluid
bolus
salin
albumin
increas
mortal
compar
children
receiv
fluid
bolus
absenc
data
demonstr
benefit
use
liber
fluid
strategi
critic
ill
patient
sepsi
ard
consid
major
patient
icu
develop
ard
suggest
initi
conserv
approach
fluid
resuscit
patient
shock
acut
resuscit
adult
shock
recommend
use
crystalloid
colloid
strong
recommend
moder
qualiti
evid
sinc
exist
direct
evid
shock
patient
panel
base
recommend
indirect
evid
critic
ill
patient
gener
systemat
review
rct
n
patient
compar
use
crystalloid
versu
colloid
critic
ill
patient
outcom
favor
use
colloid
consid
colloid
harm
see
colloid
costli
crystalloid
avail
colloid
limit
set
eg
lowand
middleincom
countri
recommend
use
crystalloid
fluid
resuscit
patient
shock
acut
resuscit
adult
shock
suggest
use
bufferedbalanc
crystalloid
unbalanc
crystalloid
weak
recommend
moder
qualiti
evid
direct
evid
address
question
patient
shock
panel
therefor
base
recommend
indirect
evid
critic
ill
patient
gener
systemat
review
metaanalysi
rct
n
patient
compar
intraven
buffer
balanc
crystalloid
solut
versu
salin
resuscit
critic
ill
adult
children
report
signific
differ
hospit
mortal
ci
acut
kidney
injuri
ci
treatment
howev
point
estim
outcom
suggest
potenti
benefit
buffer
crystalloid
solut
absenc
appar
harm
consid
roughli
equival
cost
suggest
use
buffer
crystalloid
solut
unbalanc
crystalloid
solut
resuscit
patient
shock
set
limit
avail
buffer
solut
salin
remain
reason
altern
acut
resuscit
adult
shock
recommend
use
hydroxyethyl
starch
strong
recommend
moder
qualiti
evid
given
absenc
direct
evid
patient
shock
panel
base
recommend
indirect
evid
critic
ill
patient
gener
systemat
review
rct
n
patient
compar
use
crystalloid
versu
colloid
critic
ill
patient
rct
n
patient
compar
use
crystalloid
use
starch
data
pool
statist
signific
differ
mortal
observ
end
followup
rr
ci
within
day
rr
ci
within
day
rr
ci
author
howev
report
increas
risk
blood
transfus
rr
ci
renal
replac
therapi
rrt
starch
rr
ci
given
risk
clinic
signific
harm
appar
absenc
benefit
use
hydroxyethyl
starch
recommend
use
resuscit
patient
shock
acut
resuscit
adult
shock
suggest
use
gelatin
weak
recommend
lowqual
evid
studi
evalu
question
patient
shock
panel
base
recommend
indirect
evid
critic
ill
patient
gener
systemat
review
rct
n
patient
compar
crystalloid
versu
colloid
use
critic
ill
patient
crystalloid
compar
gelatin
rct
n
statist
signific
differ
allcaus
mortal
observ
end
followup
rr
ci
acut
resuscit
adult
shock
suggest
use
dextran
weak
recommend
lowqual
evid
given
absenc
direct
evid
patient
shock
panel
base
recommend
indirect
evid
critic
ill
patient
gener
systemat
review
metaanalysi
crystalloid
versu
colloid
use
critic
ill
patient
identifi
trial
compar
crystalloid
dextran
n
report
similar
mortal
rate
end
followup
rr
ci
within
day
rr
ci
possibl
increas
risk
blood
transfus
dextran
arm
rr
ci
view
possibl
increas
risk
blood
transfus
bleed
higher
cost
associ
dextran
suggest
use
resuscit
patient
shock
acut
resuscit
adult
shock
suggest
routin
use
albumin
initi
resuscit
weak
recommend
moder
qualiti
evid
sinc
direct
evid
patient
shock
panel
base
recommend
indirect
evid
critic
ill
patient
gener
systemat
review
metaanalysi
identifi
rct
n
compar
albumin
crystalloid
use
demonstr
signific
differ
allcaus
mortal
end
followup
rr
ci
within
day
rr
ci
within
rr
ci
risk
blood
transfus
rr
ci
rrt
rr
ci
also
similar
absenc
benefit
albumin
consid
cost
limit
avail
suggest
routin
use
initi
resuscit
patient
shock
adult
shock
suggest
use
norepinephrin
firstlin
vasoact
agent
agent
weak
recommend
lowqual
evid
direct
evid
patient
shock
therefor
panel
base
recommend
indirect
evid
critic
ill
patient
gener
systemat
review
rct
n
patient
clinic
practic
guidelin
summar
avail
bodi
evid
best
firstlin
vasopressor
patient
shock
norepinephrin
wide
studi
vasoact
agent
low
priori
risk
undesir
effect
suggest
use
norepinephrin
firstlin
vasoact
agent
patient
shock
norepinephrin
avail
suggest
use
either
vasopressin
epinephrin
firstlin
vasoact
agent
vasoact
agent
adult
shock
weak
recommend
lowqual
evid
absenc
direct
evid
patient
shock
panel
base
recommend
indirect
evid
critic
ill
patient
gener
systemat
review
rct
n
patient
norepinephrin
compar
vasopressin
epinephrin
trial
directli
compar
two
option
norepinephrin
avail
suggest
use
either
vasopressin
epinephrin
agent
assess
rct
without
show
clear
evid
harm
factor
determin
choic
vasopressin
epinephrin
may
includ
avail
contraind
two
agent
vasopressin
digit
ischemia
may
concern
epinephrin
tachycardia
excess
lactat
product
may
consider
adult
shock
recommend
use
dopamin
norepinephrin
avail
strong
recommend
high
qualiti
evid
direct
evid
address
question
patient
shock
panel
base
recommend
indirect
evid
critic
ill
patient
cochran
systemat
review
found
six
rct
n
compar
norepinephrin
dopamin
patient
shock
pool
result
show
signific
differ
allcaus
mortal
point
estim
favor
norepinephrin
rr
ci
increas
risk
arrhythmia
rr
ci
found
dopamin
arm
basi
increas
risk
harm
includ
possibl
increas
risk
mortal
patient
treat
dopamin
recommend
use
dopamin
patient
shock
norepinephrin
altern
avail
see
recommend
adult
shock
suggest
ad
vasopressin
secondlin
agent
titrat
norepinephrin
dose
target
mean
arteri
pressur
map
achiev
norepinephrin
alon
weak
recommend
moder
qualiti
evid
critic
care
medicin
wwwccmjournalorg
absenc
data
patient
shock
panel
base
recommend
indirect
evid
critic
ill
patient
gener
recent
clinic
practic
guidelin
use
vasopressin
vasopressin
analog
critic
ill
adult
distribut
shock
assess
analyz
rct
n
patient
author
found
low
certainti
reduct
mortal
rr
ci
high
certainti
reduct
atrial
fibril
rr
ci
moder
certainti
increas
risk
digit
ischemia
rr
ci
addit
vasopressin
analog
catecholamin
anoth
recent
systemat
review
reach
similar
conclus
view
find
suggest
ad
vasopressin
secondlin
agent
titrat
norepinephrin
dose
target
map
achiev
norepinephrin
alon
patient
shock
adult
shock
suggest
titrat
vasoact
agent
target
map
mm
hg
rather
higher
map
target
weak
recommend
lowqual
evid
direct
evid
inform
recommend
base
indirect
evid
critic
ill
patient
recent
individu
patientdata
metaanalysi
two
rct
n
patient
compar
higher
versu
lower
blood
pressur
target
vasopressor
therapi
adult
patient
shock
report
signific
differ
indic
improv
outcom
lower
map
target
firm
indic
harm
suggest
titrat
vasoact
agent
target
mm
hg
adult
shock
evid
cardiac
dysfunct
persist
hypoperfus
despit
fluid
resuscit
norepinephrin
suggest
ad
dobutamin
increas
norepinephrin
dose
weak
recommend
lowqual
evid
absenc
direct
evid
patient
shock
panel
use
indirect
evid
critic
ill
patient
inform
recommend
clinic
practic
guidelin
assess
optim
inotrop
agent
patient
acut
circulatori
failur
shock
rct
compar
dobutamin
vs
placebo
treatment
identifi
base
physiolog
rational
suggest
ad
dobutamin
treatment
patient
shock
evid
cardiac
dysfunct
persist
hypoperfus
despit
fluid
resuscit
high
dose
norepinephrin
use
dobutamin
shock
includ
patient
shock
research
prioriti
adult
refractori
shock
suggest
use
lowdos
corticosteroid
therapi
shockrevers
corticosteroid
therapi
weak
recommend
lowqual
evid
typic
corticosteroid
regimen
septic
shock
intraven
hydrocortison
mg
per
day
administ
either
infus
intermitt
dose
data
exist
use
steroid
patient
shock
panel
base
recommend
indirect
evid
critic
ill
patient
gener
time
resolut
shock
length
stay
especi
icu
import
cost
consider
suggest
use
lowdos
corticosteroid
therapi
patient
refractori
shock
provid
guidanc
patient
respiratori
failur
absenc
refractori
shock
preval
hypox
respiratori
failur
patient
recent
report
china
show
patient
studi
receiv
noninvas
posit
pressur
ventil
nippv
requir
invas
mechan
ventil
tabl
although
true
incid
hypox
respiratori
failur
patient
clear
appear
develop
sever
diseas
requir
oxygen
therapi
requir
icu
admiss
mechan
ventil
anoth
studi
report
critic
ill
patient
patient
ard
receiv
highflow
nasal
cannula
hfnc
invas
mechan
ventil
nippv
wwwccmjournalorg
xxx
volum
xxx
number
xxx
risk
factor
respiratori
failur
risk
factor
associ
respiratori
failur
requir
mechan
ventil
clearli
describ
publish
report
although
limit
avail
data
risk
factor
associ
critic
illnessicu
admiss
includ
older
age
year
male
gender
presenc
underli
comorbid
diabet
malign
immunocompromis
state
cdc
report
overal
casefat
rate
cfr
cfr
patient
age
year
older
critic
ill
patient
cfr
higher
receiv
invas
mechan
ventil
presenc
preexist
comorbid
condit
cardiovascular
diseas
diabet
chronic
respiratori
diseas
hypertens
cancer
associ
higher
risk
death
adult
suggest
start
supplement
oxygen
peripher
oxygen
satur
spo
weak
recommend
lowqual
evid
recommend
start
supplement
oxygen
spo
strong
recommend
moder
qualiti
evid
adult
acut
hypoxem
respiratori
failur
oxygen
recommend
spo
maintain
higher
strong
recommend
moder
qualiti
evid
recent
studi
describ
diseas
cours
patient
china
show
hospit
patient
sever
diseas
requir
supplement
oxygen
critic
ill
patient
hypoxia
detriment
associ
poor
outcom
random
nonrandom
studi
use
oxygen
adult
howev
panel
use
indirect
evid
acut
ill
popul
inform
recommend
systemat
review
metaanalysi
rct
patient
show
liber
oxygen
strategi
associ
increas
risk
hospit
mortal
rr
ci
acut
ill
patient
furthermor
metaregress
show
linear
associ
risk
death
higher
spo
target
median
spo
liber
oxygen
group
iqr
across
trial
recent
clinic
practic
guidelin
recommend
spo
maintain
higher
subsequ
trial
provid
guidanc
oxygen
target
icurox
trial
random
critic
ill
patient
receiv
either
conserv
oxygen
base
protocol
dial
oxygen
usual
care
trial
show
differ
mortal
two
group
ci
icurox
trial
compar
hyperoxia
conserv
oxygen
strategi
instead
compar
usual
care
conserv
oxygen
strategi
recent
trial
random
patient
ard
conserv
oxygen
arm
target
spo
liber
oxygen
arm
target
spo
trial
stop
earli
futil
possibl
harm
death
occur
includ
patient
mortal
risk
differ
rd
ci
day
conserv
oxygen
arm
higher
risk
death
rd
ci
consid
associ
patient
harm
extrem
spo
target
increas
cost
liber
oxygen
use
well
potenti
reduc
equiti
oxygen
resourc
deplet
panel
issu
strong
recommend
use
oxygen
target
spo
strong
recommend
avoid
lower
valu
spo
therefor
reason
spo
rang
patient
receiv
oxygen
adult
acut
hypoxem
respiratori
failur
despit
convent
oxygen
therapi
suggest
use
hfnc
convent
oxygen
therapi
weak
recommend
lowqual
evid
direct
evid
patient
panel
use
indirect
evid
critic
ill
popul
inform
recommend
rct
compar
hfnc
convent
oxygen
therapi
patient
acut
hypox
respiratori
failur
hfnc
result
reduc
mortal
ci
reduc
risk
intub
systemat
review
metaanalysi
nine
rct
patient
show
hfnc
reduc
intub
compar
convent
oxygen
rr
ci
affect
risk
death
icu
length
stay
even
though
evid
mortal
length
stay
strong
reduct
need
intub
import
find
particularli
perspect
pandem
resourc
critic
care
bed
ventil
may
becom
limit
addit
sar
report
increas
transmiss
diseas
healthcar
worker
especi
nurs
endotrach
intub
cl
although
find
base
mostli
retrospect
observ
studi
hfnc
seem
confer
increas
risk
transmiss
diseas
studi
evalu
bacteri
environment
contamin
hfnc
present
contamin
risk
similar
convent
oxygen
sar
healthcar
worker
expos
hfnc
increas
risk
develop
diseas
final
patient
may
find
hfnc
comfort
least
comfort
convent
oxygen
therapi
although
author
advis
avoid
use
hfnc
patient
due
fear
diseas
transmiss
studi
support
advic
lack
although
propos
patient
wear
face
mask
hfnc
therapi
uncertain
efficaci
safeti
approach
question
could
address
futur
studi
adult
acut
hypoxem
respiratori
failur
suggest
use
hfnc
nippv
weak
recommend
lowqual
evid
adult
acut
respiratori
failur
suggest
use
hfnc
nippv
rct
compar
hfnc
nippv
patient
acut
hypox
respiratori
failur
hfnc
result
reduc
mortal
day
hr
ci
significantli
affect
need
intub
failur
rate
nippv
vs
convent
oxygen
hfnc
group
p
anoth
metaanalysi
compar
hfnc
nippv
show
hfnc
decreas
need
intub
patient
yet
without
significantli
reduc
mortal
icu
length
stay
addit
patient
may
find
hfnc
comfort
nippv
given
evid
decreas
risk
intub
hfnc
compar
nippv
acut
hypoxem
respiratori
failur
studi
suggest
nippv
may
carri
greater
risk
nosocomi
infect
healthcar
provid
suggest
hfnc
nippv
howev
patient
receiv
hfnc
nippv
monitor
close
care
set
intub
facilit
event
decompens
failur
rate
may
high
emerg
intub
uncontrol
set
may
increas
risk
nosocomi
infect
healthcar
provid
adult
acut
hypoxem
respiratori
failur
hfnc
avail
urgent
indic
endotrach
intub
suggest
trial
nippv
close
monitor
shortinterv
assess
worsen
respiratori
failur
weak
recommend
lowqual
evid
abl
make
recommend
regard
use
helmet
nippv
compar
mask
nippv
option
certain
safeti
efficaci
adult
receiv
nippv
hfnc
recommend
close
monitor
worsen
respiratori
statu
earli
intub
control
set
worsen
occur
best
practic
statement
adult
present
hypox
respiratori
failur
direct
evid
support
use
nippv
furthermor
prior
studi
suggest
may
associ
increas
risk
infect
transmiss
healthcar
worker
metaanalys
rct
show
reduct
intub
mortal
risk
nippv
hypox
respiratori
failur
howev
metaanalys
includ
studi
focus
immunocompromis
acut
cardiogen
pulmonari
edema
postop
patient
find
may
therefor
less
applic
patient
acut
hypoxem
respiratori
failur
ard
common
present
acut
hypoxem
respiratori
failur
etiolog
cardiogen
pulmonari
edema
nippv
high
failur
rate
one
rct
failur
report
patient
hypox
respiratori
failur
ventil
nippv
patient
therefor
requir
intub
addit
patient
hypox
respiratori
failur
random
nippv
higher
mortal
ci
treat
convent
oxygen
therapi
ci
hfnc
ci
p
cohort
middl
east
respiratori
syndrom
mer
patient
nippv
associ
improv
mortal
length
stay
compar
patient
intub
without
tri
nippv
howev
nippv
associ
high
failur
rate
lead
intub
patient
receiv
nippv
prior
intub
increas
inhal
nitric
oxid
requir
increas
mortal
failur
rate
pandem
influenza
sar
rang
demonstr
efficaci
mainli
come
case
seri
observ
studi
rather
rct
lead
practic
variat
china
use
nippv
pandem
respiratori
infect
common
wherea
guidelin
europ
hong
kong
us
advis
nippv
firstlin
therapi
addit
concern
use
nippv
respiratori
pandem
like
nippv
may
aggrav
sever
form
lung
injuri
result
injuri
transpulmonari
pressur
larg
tidal
volum
may
delay
initi
invas
mechan
ventil
lead
emerg
unstabl
intub
increas
risk
transmiss
healthcar
team
addit
nippv
aerosolgener
procedur
increas
risk
transmiss
diseas
healthcar
worker
sever
studi
metaanalys
sar
also
highlight
risk
nosocomi
spread
diseas
nippv
balanc
benefit
harm
use
nippv
adult
unclear
certain
patient
form
respiratori
failur
acut
hypercapn
respiratori
failur
acut
cardiogen
pulmonari
edema
known
caus
respiratori
failur
nippv
may
benefici
howev
limit
experi
nippv
pandem
suggest
high
failur
rate
recommend
patient
receiv
nippv
monitor
close
care
set
intub
facilit
event
decompens
howev
resourc
becom
stretch
may
insuffici
abil
provid
invas
ventil
even
moder
chanc
success
nippv
may
justifi
use
nippv
use
helmet
nippv
attract
option
avail
singlecent
rct
show
decreas
intub
improv
mortal
nippv
deliv
helmet
ard
patient
particular
import
set
pandem
nippv
helmet
also
shown
reduc
exhal
air
dispers
wherea
face
mask
insuffici
howev
helmet
nippv
expens
wwwccmjournalorg
xxx
volum
xxx
number
xxx
without
direct
evid
benefit
patient
resourc
util
acquir
equip
alreadi
avail
figur
summar
recommend
hfnc
nippv
patient
mechan
ventil
adult
ard
recommend
use
low
tidal
volum
vt
ventil
vt
mlkg
predict
bodi
weight
higher
tidal
volum
vt
mlkg
strong
recommend
moder
qualiti
evid
current
studi
address
mechan
ventil
strategi
patient
howev
panel
expert
believ
mechan
ventil
patient
manag
similarli
patient
acut
respiratori
failur
icu
mechan
ventil
potenti
lifesav
intervent
worsen
lung
injuri
ventilatorinduc
lung
injuri
vili
contribut
multiorgan
failur
patient
ard
one
main
ventil
strategi
minim
vili
low
vt
ventil
systemat
review
metaanalysi
rct
found
invers
associ
larger
vt
gradient
mortal
addit
author
found
use
protocol
low
vt
strategi
high
peep
rct
patient
reduc
risk
death
rr
ci
analysi
rct
patient
show
reduct
hospit
mortal
low
vt
ventil
rr
ci
basi
avail
bodi
evid
sever
guidelin
recommend
use
low
vt
ml
kg
predict
bodi
weight
patient
ard
panel
judg
magnitud
benefit
moder
cost
low
intervent
accept
feasibl
implement
therefor
issu
strong
recommend
use
low
vt
mlkg
predict
bodi
weight
ventil
patient
ard
fig
ardsnet
studi
protocol
set
initi
vt
mlkg
increas
mlkg
patient
doubl
trigger
inspiratori
airway
pressur
decreas
peep
strict
adher
target
vt
spontan
breath
patient
ard
challeng
patientventil
dyssynchroni
uncommon
panel
judg
magnitud
benefit
moder
cost
low
patient
valu
consist
intervent
accept
feasibl
implement
therefor
issu
strong
recommend
keep
pplat
cm
h
ventil
patient
ard
ardsnet
studi
protocol
set
initi
vt
mlkg
measur
pplat
inspiratori
paus
pplat
cm
h
vt
could
reduc
mlkg
mlkg
step
pplat
within
rang
mechan
ventil
adult
moder
sever
ard
suggest
use
higher
peep
strategi
lower
peep
strategi
weak
recommend
lowqual
evid
remark
use
higher
peep
strategi
ie
peep
cm
h
clinician
monitor
patient
barotrauma
ard
extrins
peep
use
prevent
repeat
open
close
alveoli
ie
atelectotrauma
therefor
reduc
vili
addit
peep
increas
sustain
alveolar
recruit
improv
oxygen
reduc
oxygen
requir
clinic
trial
examin
effect
peep
coronavirusinduc
ard
howev
larg
bodi
indirect
evid
patient
ard
individu
patient
data
metaanalysi
ipdma
three
largest
trial
patient
high
peep
found
differ
inhospit
mortal
patient
rr
ci
howev
patient
ard
higher
peep
strategi
result
lower
icu
mortal
rr
ci
lower
inhospit
mortal
rr
ci
reduct
use
rescu
therapi
rr
ci
expens
possibl
increas
risk
pneumothorax
recent
systemat
review
metaanalysi
nine
rct
patient
examin
effect
higher
peep
strategi
patientimport
outcom
overal
higher
peep
strategi
reduc
hospit
mortal
rr
ci
howev
subgroup
trial
enrol
patient
oxygen
respons
peep
rct
patient
use
high
peep
significantli
reduc
inhospit
mortal
compar
lower
peep
strategi
rr
ci
although
bodi
evid
suggest
benefici
effect
higher
peep
select
patient
result
like
confound
fact
low
vt
ventil
use
control
arm
trial
clear
agre
upon
definit
higher
peep
moreov
optim
peep
level
ard
patient
unknown
like
vari
base
extent
diseas
ipdma
combin
differ
strategi
set
higher
peep
reason
start
point
would
implement
strategi
use
larg
rct
includ
ie
alveoli
lov
express
increas
peep
level
clinician
monitor
patient
evid
barotrauma
importantli
higher
peep
may
result
higher
pplat
associ
risk
benefit
pplat
cm
h
clinician
use
ard
network
protocol
strategi
determin
optim
peep
level
avail
strategi
includ
decrement
peep
strategi
esophag
balloon
techniqu
electr
imped
tomographi
howev
effect
use
techniqu
clinic
outcom
unknown
ard
suggest
use
conserv
fluid
strategi
liber
fluid
strategi
weak
recommend
lowqual
evid
optim
fluid
strategi
known
howev
plausibl
patient
respond
fluid
similarli
ard
patient
limit
data
avail
show
cardiac
failur
alon
combin
respiratori
failur
caus
death
anoth
studi
show
patient
arrhythmia
furthermor
major
patient
icu
elderli
may
develop
myocardi
dysfunct
could
limit
abil
handl
larg
fluid
volum
view
moder
benefit
observ
ard
popul
possibl
reduc
cost
administ
less
fluid
feasibl
intervent
panel
issu
weak
recommend
favor
conserv
fluid
strategi
patient
ard
mechan
ventil
adult
moder
sever
ard
suggest
prone
ventil
hour
prone
ventil
weak
recommend
lowqual
evid
seri
patient
radiograph
featur
progress
first
week
symptom
onset
predomin
ground
glass
opac
mix
pattern
predomin
basilar
consolid
latter
pattern
may
suggest
role
prone
ventil
prone
posit
theoret
make
ventil
homogen
decreas
ventral
alveolar
distent
dorsal
alveolar
collaps
may
reduc
differ
dorsal
ventral
transpulmonari
pressur
addit
reduc
lung
compress
improv
perfus
recent
studi
describ
clinic
cours
icu
show
prone
ventil
use
patient
howev
studi
avail
describ
clinic
cours
patient
ventil
prone
posit
recent
systemat
review
metaanalysi
nine
rct
patient
show
prone
ventil
least
hour
patient
moder
sever
ard
reduc
mortal
rct
rr
ci
effect
mortal
studi
use
prone
ventil
hour
rct
rr
ci
hand
prone
ventil
increas
risk
pressur
sore
rr
ci
endotrach
tube
obstruct
rr
ci
systemat
review
reach
similar
conclus
moder
certainti
prone
ventil
hour
patient
moder
sever
ard
reduc
mortal
may
increas
risk
pressur
sore
endotrach
tube
obstruct
healthcar
worker
prone
patient
train
proper
techniqu
prone
take
infect
control
precaut
event
accident
endotrach
tube
disconnect
ventil
prone
associ
signific
cost
believ
may
provid
signific
benefit
prone
implement
lowand
middleincom
set
effort
made
provid
necessari
train
educ
healthcar
worker
facilit
practic
http
wwwyoutubecomwatch
protocol
prone
use
institut
base
avail
resourc
level
train
prone
ventil
use
healthcar
worker
awar
complic
pressur
sore
vascular
line
endotrach
tube
displac
facial
edema
transient
hemodynam
instabl
corneal
abras
brachial
plexu
injuri
hemodialysi
vascular
access
flow
issu
addit
clinician
familiar
absolut
contraind
prone
ventil
unstabl
spine
open
abdomen
open
chest
ie
surgeri
trauma
enter
nutrit
via
nasogastr
nasoduoden
tube
continu
prone
mechan
ventil
adult
moder
sever
ard
suggest
use
need
intermitt
bolus
neuromuscular
block
agent
nmba
continu
nmba
infus
facilit
protect
lung
ventil
weak
recommend
lowqual
evid
event
persist
ventil
dyssynchroni
need
ongo
deep
sedat
prone
ventil
persist
high
plateau
pressur
suggest
use
continu
nmba
infus
hour
weak
recommend
lowqual
evid
sever
profession
societi
issu
recommend
use
nmba
ard
issu
recommend
favor
use
nmba
infus
patient
moder
sever
ard
recommend
mostli
base
pool
estim
three
rct
patient
show
reduct
mortal
nmba
infus
compar
nmba
infus
howev
result
reevalu
system
earli
neuromuscular
blockad
rose
trial
challeng
previou
trial
rose
trial
investig
random
patient
moder
sever
ard
receiv
either
infus
nmba
hour
intermitt
nmba
bolus
need
basi
rose
trial
show
continu
infus
cisatracurium
improv
patient
import
outcom
due
differ
design
rose
trial
earlier
trial
perform
metaanalysi
mortal
outcom
although
pool
estim
barotrauma
favor
continu
nmba
infus
rr
ci
panel
suggest
continu
nmba
infus
reserv
patient
indic
ongo
paralysi
intermitt
dose
may
suffic
patient
persist
ventil
dyssynchroni
patient
need
ongo
deep
sedat
prone
ventil
persist
high
plateau
pressur
effect
nmba
longterm
outcom
unclear
recommend
routin
use
inhal
nitric
oxid
strong
recommend
lowqual
evid
mechan
ventil
adult
sever
ard
hypoxemia
despit
optim
ventil
rescu
strategi
suggest
trial
inhal
pulmonari
vasodil
rescu
therapi
rapid
improv
oxygen
observ
treatment
taper
weak
recommend
lowqual
evid
studi
describ
use
pulmonari
vasodil
patient
cochran
review
identifi
rct
patient
inhal
nitric
oxid
ard
treatment
show
signific
effect
mortal
rr
ci
associ
increas
risk
acut
kidney
injuri
rr
ci
inhal
nitric
oxid
result
transient
improv
oxygen
subgroup
studi
report
pao
fio
mm
hg
valu
hour
intervent
show
statist
signific
differ
favor
inhal
nitric
oxid
present
beyond
hour
studi
assess
use
inhal
nitric
oxid
rescu
therapi
possibl
harm
inhal
nitric
oxid
absenc
clear
mortal
benefit
panel
issu
strong
recommend
routin
use
patient
ard
howev
view
find
improv
oxygen
trial
inhal
nitric
oxid
rescu
therapi
tri
option
reason
avail
inhal
nitric
oxid
use
without
good
respons
term
oxygen
taper
avoid
rebound
pulmonari
vasoconstrict
occur
prolong
use
abrupt
discontinu
adequ
power
rct
evalu
inhal
prostacyclin
ilioprost
therefor
could
recommend
use
sever
ard
mechan
ventil
adult
hypoxemia
despit
optim
ventil
suggest
use
recruit
maneuv
use
recruit
maneuv
weak
recommend
lowqual
evid
recruit
maneuv
use
recommend
use
staircas
increment
peep
recruit
maneuv
strong
recommend
moder
qualiti
evid
studi
assess
role
recruit
maneuv
rm
patient
ard
secondari
rm
aim
improv
oxygen
increas
transpulmonari
pressur
open
atelectat
alveoli
howev
exposur
high
level
posit
pressur
may
lead
barotrauma
well
caus
transient
hypotens
alreadi
critic
ill
unstabl
patient
assess
eight
indirect
rct
assess
rm
ard
patient
includ
patient
sepsi
due
bacteri
viral
pneumonia
vari
strategi
use
help
recruit
atelectat
lung
howev
two
strategi
particular
common
wwwccmjournalorg
xxx
volum
xxx
number
xxx
rct
includ
metaanalysi
tradit
rm
describ
prolong
inspiratori
hold
set
durat
time
higher
level
cpap
commonli
cm
h
second
increment
peep
titrat
rm
describ
increment
increas
peep
cm
h
minut
systemat
review
metaanalysi
rct
patient
rm
reduc
mortal
use
rescu
intervent
improv
oxygen
hour
without
increas
risk
barotrauma
similarli
identifi
eight
rct
patient
report
inhospit
mortal
studi
rm
associ
reduc
mortal
rr
ci
howev
subgroup
analys
suggest
tradit
rm
significantli
reduc
mortal
rr
ci
wherea
increment
peep
titrat
rm
increas
mortal
rr
ci
effect
rm
oxygen
may
transient
studi
show
signific
improv
oxygen
hour
trial
use
differ
peep
strategi
intervent
control
arm
rm
best
combin
higher
peep
strategi
patient
sever
ard
hypoxemia
may
benefit
tradit
recruit
maneuv
along
higher
level
peep
evid
specif
need
patient
receiv
rm
monitor
close
sever
desatur
hypotens
barotrauma
rm
stop
lead
patient
deterior
mechan
ventil
adult
refractori
hypoxemia
despit
optim
ventil
use
rescu
therapi
prone
suggest
use
venoven
vv
ecmo
avail
refer
patient
ecmo
center
weak
recommend
lowqual
evid
remark
due
resourceintens
natur
ecmo
need
experienc
center
healthcar
worker
infrastructur
ecmo
consid
care
select
patient
sever
ard
clinic
trial
ecmo
patient
recent
report
china
suggest
case
icu
receiv
ecmo
clinic
cours
outcom
patient
report
yet
ministri
health
saudi
arabia
establish
ecmo
program
merscov
epidem
retrospect
cohort
studi
patient
merscov
refractori
hypoxemia
group
patient
receiv
vv
ecmo
lower
inhospit
mortal
vs
p
howev
cohort
studi
high
risk
select
bia
given
retrospect
design
two
rct
evalu
ecmo
vs
convent
mechan
ventil
sever
ard
guidelin
publish
unabl
provid
specif
guidanc
use
ecmo
research
recommend
although
recent
rct
eolia
stop
earli
futil
reanalysi
trial
use
bayesian
approach
provid
favor
interpret
suggest
lower
mortal
ecmo
sever
ard
recent
systemat
review
includ
two
rct
patient
found
reduct
mortal
ecmo
rr
ci
risk
major
bleed
higher
ecmo
ecmo
resourceintens
techniqu
restrict
special
center
remain
extrem
limit
resourc
therefor
use
rescu
therapi
reserv
care
select
patient
futur
studi
describ
outcom
patient
ecmo
mechan
death
advanc
understand
guid
practic
section
discuss
possibl
treatment
option
complic
includ
antivir
agent
immunosuppress
agent
immunomodul
therapi
cytokin
storm
syndrom
hyperinflammatori
state
character
fulmin
multiorgan
failur
elev
cytokin
level
recent
studi
china
show
associ
cytokin
elev
profil
reminisc
secondari
hemophagocyt
lymphohistiocytosi
hlh
author
even
suggest
screen
critic
ill
patient
secondari
hlh
use
hscore
corticosteroid
immunosuppress
agent
use
patient
high
likelihood
hlh
evid
need
make
recommend
treatment
option
cytokin
storm
mechan
ventil
adult
respiratori
failur
without
ard
suggest
routin
use
system
corticosteroid
weak
recommend
lowqual
evid
mechan
ventil
adult
ard
suggest
use
system
corticosteroid
use
corticosteroid
weak
recommend
lowqual
evid
major
panel
support
weak
recommend
ie
suggest
use
steroid
sickest
patient
ard
howev
lowqual
evid
expert
panel
prefer
issu
recommend
higher
qualiti
direct
evid
avail
control
clinic
trial
use
corticosteroid
patient
coronavirus
publish
peerreview
report
patient
sever
report
use
methylprednisolon
mgkgday
day
associ
shorter
durat
supplement
oxygen
use
day
vs
day
p
improv
radiograph
find
although
interest
judg
preliminari
report
insuffici
basi
formul
recommend
due
risk
confound
therefor
use
indirect
evid
commun
acquir
pneumonia
ard
viral
infect
inform
recommend
sever
rct
use
system
corticosteroid
hospit
patient
communityacquir
pneumonia
mostli
nonicu
patient
sepsi
septic
shock
systemat
review
metaanalysi
rct
show
use
corticosteroid
may
reduc
need
mechan
ventil
rct
patient
rr
ci
ard
rct
patient
rr
ci
durat
hospit
rct
patient
md
day
ci
increas
risk
hyperglycemia
requir
treatment
howev
trial
includ
differ
popul
effect
mortal
outcom
unclear
use
differ
drug
dose
regimen
addit
concern
corticosteroid
use
viral
pneumonia
therefor
result
may
generaliz
popul
mani
publish
observ
studi
use
steroid
viral
pneumonia
ie
influenza
viru
coronavirus
other
prone
confound
sicker
patient
usual
receiv
corticosteroid
updat
recent
cochran
review
use
corticosteroid
influenza
search
studi
coronavirus
includ
total
cohort
studi
influenza
coronavirus
metaanalysi
adjust
or
show
associ
corticosteroid
use
increas
mortal
ci
effect
patient
coronavirus
unclear
ci
also
studi
limit
signific
heterogen
found
signific
homogen
observ
studi
use
corticosteroid
ard
caus
coronavirus
gener
viral
ard
respect
furthermor
case
summari
statist
tend
toward
harm
use
steroid
updat
recent
cochran
review
identifi
addit
rct
deal
ard
overal
includ
seven
rct
enrol
patient
ard
use
corticosteroid
reduc
mortal
rr
ci
durat
mechan
ventil
md
day
ci
howev
trial
focus
viral
ard
limit
generaliz
result
patient
addit
review
observ
studi
corticosteroid
use
viral
ard
identifi
cohort
studi
although
point
estim
show
increas
mortal
ci
includ
substanti
harm
benefit
ci
recent
rct
interest
trial
use
recombin
interferon
rifn
reduc
mortal
ard
patient
subgroup
patient
receiv
corticosteroid
rifn
use
associ
increas
mortal
ci
direct
evid
come
retrospect
cohort
studi
patient
pneumonia
studi
show
associ
corticosteroid
use
lower
mortal
patient
ard
hr
ci
howev
estim
adjust
confound
factor
effect
corticosteroid
patient
sepsi
septic
shock
may
differ
recent
systemat
review
metaanalys
rct
sepsi
show
small
improv
mortal
faster
resolut
shock
corticosteroid
use
compar
use
corticosteroid
see
previou
section
hemodynam
support
wide
recogn
corticosteroid
rang
advers
effect
viral
pneumonia
icu
sever
studi
show
increas
viral
shed
corticosteroid
use
potenti
indic
viral
replic
clinic
implic
increas
viral
shed
uncertain
consid
panel
issu
suggest
routin
use
system
corticosteroid
respiratori
failur
suggest
use
corticosteroid
sicker
popul
ard
clinician
use
corticosteroid
ard
use
lower
dose
shorter
treatment
cours
mechan
ventil
patient
respiratori
failur
suggest
use
empir
antimicrobialsantibacteri
agent
antimicrobi
weak
recommend
lowqual
evid
treat
team
initi
empir
antimicrobi
assess
deescal
daili
reevalu
durat
therapi
spectrum
coverag
base
microbiolog
result
patient
clinic
statu
control
clinic
trial
evalu
use
empir
antimicrobi
patient
coronavirus
recommend
therefor
base
upon
extrapol
data
viral
pneumonia
particularli
influenza
identifi
bacteri
coinfect
superinfect
patient
challeng
symptom
may
similar
underli
viral
infect
diagnost
difficulti
reflect
high
rate
intraven
antibiot
administ
wuhan
nonsever
diseas
patient
admit
hospit
icu
data
preval
bacteri
superinfect
patient
limit
larger
case
studi
clinician
often
overwhelm
systemat
obtain
highqual
sampl
critic
ill
patient
mer
bacteri
viral
coinfect
coinfect
staphylococcu
aureu
common
influenza
pneumonia
especi
virul
recent
clinic
practic
guidelin
recommend
initi
empir
antibacteri
therapi
adult
communityacquir
pneumonia
test
posit
wwwccmjournalorg
xxx
volum
xxx
number
xxx
influenza
data
critic
ill
patient
demonstr
secondari
infect
case
although
number
small
isol
organ
includ
gramneg
organ
k
pneumonia
p
aeruganosa
marcescen
basi
limit
data
difficult
determin
pattern
superinfect
includ
risk
aureu
infect
commonli
seen
influenza
patient
hypox
respiratori
failur
requir
mechan
ventil
panel
suggest
empir
antimicrobi
treatment
basi
superinfect
reason
common
popul
may
lead
substanti
increas
mortal
pandem
influenza
therefor
critic
ill
patient
suspect
confirm
treat
empir
antimicrobi
therapi
accord
clinic
syndrom
eg
communityacquir
hospitalacquir
pneumonia
secondari
infect
occur
patient
incid
unknown
given
limit
data
infect
treat
accord
clinic
microbiolog
data
critic
ill
adult
develop
fever
suggest
use
acetaminophenparacetamol
temperatur
control
treatment
weak
recommend
lowqual
evid
major
patient
develop
fever
hospit
sever
diseas
largest
report
china
median
temperatur
across
patient
iqr
data
critic
ill
patient
gener
avail
review
literatur
identifi
rct
patient
examin
effect
fever
control
critic
ill
popul
exclud
neurolog
indic
temperatur
control
activ
temperatur
manag
pharmacolog
nonpharmacolog
reduc
risk
death
rr
ci
icu
length
stay
md
day
ci
effect
reduc
bodi
temperatur
md
ci
lower
given
safeti
acetaminophen
lack
harm
bodi
evid
increas
patient
comfort
fever
manag
mayb
import
therefor
issu
suggest
clinician
consid
use
pharmacolog
agent
control
fever
patient
use
nonsteroid
antiinflammatori
drug
treat
fever
patient
continu
debat
evid
avail
suggest
use
acetaminophenparacetamol
treat
fever
critic
ill
adult
suggest
routin
use
standard
intraven
immunoglobulin
ivig
weak
recommend
lowqual
evid
use
intraven
immunoglobulin
ivig
report
sever
seri
patient
efficaci
data
avail
absenc
adequ
titer
neutral
antibodi
standard
intraven
immunoglobulin
unlik
biolog
effect
ivig
may
immunomodulatori
action
use
rare
also
associ
increas
risk
seriou
advers
event
includ
anaphylact
reaction
asept
mening
renal
failur
thromboembol
hemolyt
reaction
transfusionrel
lung
injuri
late
reaction
prepar
polyclon
monoclon
antibodi
develop
howev
data
recent
trial
use
antibodybas
therapi
immun
plasma
hyperimmun
globulin
monoclon
antibodi
hemagglutinin
stalk
hospit
season
influenza
patient
demonstr
improv
outcom
critic
ill
adult
suggest
routin
use
convalesc
plasma
weak
recommend
lowqual
evid
convalesc
plasma
obtain
patient
recov
suggest
potenti
therapi
may
provid
passiv
immun
antibodi
convalesc
plasma
use
treat
sever
viral
infect
includ
caus
sar
coronaviru
avian
influenza
viru
influenza
viru
recent
metaanalysi
observ
studi
use
passiv
immunotherapi
treatment
sever
acut
respiratori
infect
viral
etiolog
suggest
convalesc
plasma
therapi
associ
reduct
mortal
ci
current
outbreak
china
convalesc
plasma
use
patient
howev
data
efficaci
safeti
convalesc
plasma
limit
target
suffici
level
neutral
antibodi
titer
unknown
studi
mer
conclud
use
convalesc
plasma
might
feasibl
challeng
due
small
pool
potenti
donor
suffici
high
antibodi
titer
rct
patient
confirm
ebola
viru
diseas
show
convalesc
plasma
unknown
level
neutral
antibodi
associ
improv
surviv
anoth
rct
patient
season
influenza
treat
hightit
versu
lowtit
antiinfluenza
immun
plasma
termin
futil
lack
effect
primari
outcom
measur
ordin
scale
clinic
statu
day
given
lack
convinc
evid
rct
uncertainti
surround
optim
prepar
convalesc
plasma
safeti
suggest
routin
use
treat
patient
evid
avail
critic
ill
adult
suggest
routin
use
lopinavirritonavir
weak
recommend
lowqual
evid
insuffici
evid
issu
recommend
use
antivir
agent
critic
ill
adult
prolong
detect
rna
respiratori
tract
sometim
site
serious
ill
patient
provid
rational
administr
antivir
agent
reduc
replic
effort
improv
clinic
outcom
present
directact
antivir
proven
inhibit
replic
provid
clinic
benefit
mer
patient
consider
number
agent
approv
indic
propos
use
comment
address
promis
one
sever
other
undergo
test
eg
arbidol
umifenovir
favipiravir
ribavirin
tradit
chines
medicin
inhal
interferon
alon
combin
one
countri
lopinavir
antiretrovir
proteas
inhibitor
use
combin
ritonavir
ensur
adequ
lopinavir
exposur
treatment
human
immunodefici
viru
hiv
infect
found
show
vitro
activ
sarscov
lopinavirritonavir
administ
combin
highdos
oral
ribavirin
taper
cours
system
corticosteroid
cohort
patient
sar
found
associ
significantli
fewer
advers
clinic
outcom
ard
death
compar
ribavirin
alon
use
histor
control
receiv
ribavirin
corticosteroid
highthroughput
screen
antivir
compound
lopinavir
inhibit
replic
merscov
vitro
anim
model
merscov
infect
treatment
lopinavirritonavir
associ
virolog
histolog
clinic
improv
versu
placebo
lopinavirritonavir
combin
interferon
beta
test
rct
merscov
patient
combin
consid
second
candid
research
priorit
list
therapeut
agent
drug
gener
good
safeti
profil
may
interact
mani
drug
commonli
use
critic
ill
patient
http
recent
rct
compar
use
lopinavirritonavir
usual
care
hospit
patient
china
trial
lopinavirritonavir
significantli
reduc
mortal
rd
ci
time
clinic
improv
md
day
ci
addit
lopinavirritonavir
associ
advers
event
trial
avail
direct
evid
use
lopinavirritonavir
patient
howev
sever
limit
trial
unblind
enrol
small
number
patient
n
small
number
event
death
total
limit
confid
result
nevertheless
routin
use
lopinavirritonavir
critic
ill
patient
probabl
warrant
weak
recommend
routin
use
lopinavirritonavir
critic
ill
patient
reason
lopinavirritonavir
one
arm
plan
core
treatment
protocol
hospit
patient
remapcap
random
embed
multifactori
adapt
platform
trial
communityacquir
pneumonia
trial
result
ongo
trial
help
increas
precis
estim
certainti
evid
remdesivir
prodrug
adenosin
analog
incorpor
nascent
viral
rna
chain
result
prematur
termin
consid
promis
drug
inform
consult
research
priorit
candid
therapeut
agent
current
publish
case
report
publish
trial
use
remdesivir
remdesivir
demonstr
effect
inhibit
merscov
sarscov
vitro
studi
furthermor
studi
anim
model
merscov
show
effect
control
superior
lopinavirritonavir
combin
system
although
intraven
remdesivir
appear
adequ
toler
recent
rct
show
less
effect
sever
antibodi
therapi
ebola
viru
diseas
sever
ongo
rct
aim
examin
efficaci
safeti
intraven
remdesivir
sever
clinicaltrialsgov
mild
moder
clinicaltrialsgov
anoth
trial
sponsor
nation
institut
allergi
infecti
diseas
recruit
patient
usa
clinicaltrialsgov
updat
guidelin
new
evid
emerg
insuffici
evid
issu
recommend
use
recombin
rifn
alon
combin
antivir
critic
ill
adult
recombin
interferon
often
combin
ribavirin
therapi
use
patient
mer
sar
differ
prepar
recombin
rifn
shown
activ
merscov
vero
cell
rhesu
macaqu
model
merscov
infect
largest
cohort
critic
ill
patient
mer
show
ribavirin
associ
lower
mortal
ci
reduc
viral
clearanc
adjust
timevari
covari
rel
effect
differ
interferon
unknown
point
vitro
data
show
display
strongest
merscov
inhibit
among
differ
rifn
prepar
rifnunivers
wwwccmjournalorg
xxx
volum
xxx
number
xxx
time
lower
previous
report
inhibitori
concentr
rct
examin
effect
combin
lopinavir
ritonavir
mortal
hospit
patient
mer
current
recruit
patient
unpublish
data
indic
inhibit
cell
cultur
ifn
priorit
studi
insuffici
evid
issu
recommend
use
chloroquin
hydroxychloroquin
critic
ill
adult
chloroquin
metabolit
hydroxychloroquin
antimalari
agent
demonstr
antivir
effect
sarscov
vitro
prior
studi
found
inhibitori
effect
chloroquin
multipl
rna
virus
vitro
rct
treatment
dengu
chikungunya
viru
infect
influenza
prophylaxi
fail
demonstr
antivir
clinic
benefit
one
nonhuman
primat
model
chikungunya
infect
shown
chloroquin
immunomodulatori
effect
associ
delay
immun
respons
higher
level
viral
replic
wors
ill
news
brief
suggest
use
patient
show
superior
control
inhibit
exacerb
pneumonia
improv
lung
imag
find
promot
viru
neg
convers
shorten
diseas
cours
data
publish
yet
recent
consensu
document
recommend
chloroquin
phosphat
mg
twice
daili
minimum
day
dose
modif
sever
gastrointestin
side
effect
occur
sinc
chloroquin
avail
countri
hydroxychloroquin
altern
recent
studi
china
explor
variou
dose
regimen
chloroquin
hydroxychloroquin
use
physiolog
base
pharmacokinet
model
studi
found
hydroxychloroquin
potent
chloroquin
inhibit
vitro
base
model
hydroxychloroquin
load
dose
mg
twice
daili
follow
mg
twice
daili
day
recommend
recent
systemat
review
found
publish
studi
patient
pend
result
ongo
trial
unabl
issu
recommend
chloroquin
insuffici
evid
issu
recommend
use
tocilizumab
critic
ill
adult
tocilizumab
human
immunoglobulin
function
immun
respons
block
interleukin
il
receptor
bind
approv
cr
inflammatori
condit
relat
relat
inflamm
rheumatoid
arthriti
juvenil
idiopath
arthriti
sever
ill
patient
may
extrem
immun
respons
lead
sever
respiratori
failur
case
inhibit
may
help
attenu
cytokin
releas
syndrom
reduc
cytokin
concentr
acut
phase
reactant
product
ongo
trial
tocilizumab
help
address
safeti
efficaci
therapi
rheumatoid
arthriti
literatur
systemat
review
metaanalysi
six
rct
dose
mg
kg
dose
show
increas
risk
advers
event
compar
control
treatment
ci
increas
risk
infect
ci
anoth
systemat
review
metaanalysi
rct
tocilizumab
rheumatoid
arthriti
found
increas
risk
infecti
respiratori
advers
event
rr
ci
data
safeti
efficaci
tocilizumab
unabl
issu
recommend
nafamostat
synthet
serin
proteas
inhibitor
potent
inhibitor
mer
cov
nitazoxanid
antiprotozo
agent
antivir
potenti
sever
respiratori
virus
includ
influenza
parainfluenza
respiratori
syncyti
viru
rhinoviru
vitro
studi
show
nafamostat
nitazoxanid
inhibit
rct
patient
acut
uncompl
influenza
demonstr
use
nitazoxanid
reduc
durat
symptom
howev
hospit
patient
sever
acut
respiratori
infect
mexico
nitazoxanid
found
superior
placebo
would
like
acknowledg
dr
zainab
al
duhailib
kimberli
lewi
malik
farooqi
jessica
bartoszko
support
conduct
systemat
review
metaanalys
guidelin
question
supplement
digit
content
avail
articl
direct
url
citat
appear
print
text
provid
html
pdf
version
articl
journal
websit
http
journalslwwcom
ccmjournal
supplement
figur
tabl
view
supplement
document
supplement
digit
content
http
link
fund
dedic
fund
guidelin
conflict
interest
dr
yaseen
arabi
princip
investig
clinic
trial
lopinavirritonavir
interferon
middl
east
respiratori
syndrom
mer
nonpaid
consult
antivir
activ
merscoronaviru
cov
gilead
scienc
sab
biotherapeut
investig
remapcap
trial
board
member
intern
sever
acut
respiratori
emerg
infect
consortium
isar
dr
eddi
fan
declar
receiv
consult
fee
alung
technolog
cardiopulmonari
dr
maurizio
cecconi
declar
consult
work
edward
lifesci
direct
system
cheetah
medic
dr
lenni
derd
nvic
dutch
nation
icu
societi
chair
taskforc
infecti
diseas
stand
committe
member
esicm
coronaviru
taskforc
start
outbreak
chair
esicm
clinic
train
committe
unpaid
posit
dr
frederick
hyden
noncompens
consult
gilead
scienc
antivir
rvi
includ
remdesivir
regeneraon
monoclon
rvi
includ
mer
sab
biotherapeut
polyclon
antibodi
rvi
includ
mer
remain
author
disclos
potenti
conflict
interest
inform
regard
articl
email
andrewrhod
nhsnet
